Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Olsson

Showing results (201-210 of 216) with videos related to

Pageof 22
Sort By:
The Lancet. Neurology|September 7, 2014
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller, Jerry S Wolinsky, Ludwig Kappos, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosisM S Freedman, J S Wolinsky, P Truffinet, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 23, 2012
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisAaron E Miller, Paul O'Connor, Jerry S Wolinsky, et al.
Multiple Sclerosis and Related Disorders|May 31, 2016
Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studiesMathias Mäurer, Giancarlo Comi, Mark S Freedman, et al.
Neurology|May 25, 2012
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trialM S Freedman, J S Wolinsky, B Wamil, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 1, 1995
Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA134A) in healthy subjects and in patients with chronic airflow limitation. Measurement by 18F-labeling and whole-body gamma-countingV W Pike, F I Aigbirhio, C A Freemantle, et al.
Journal of Neurology|June 29, 2014
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER studyAaron E Miller, Richard Macdonell, Giancarlo Comi, et al.
Multiple Sclerosis and Related Disorders|February 10, 2016
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensionsGiancarlo Comi, Mark S Freedman, Ludwig Kappos, et al.
The Lancet. Neurology|January 28, 2014
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialChristian Confavreux, Paul O'Connor, Giancarlo Comi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 1, 2013
Magnetic resonance imaging outcomes from a phase III trial of teriflunomideJerry S Wolinsky, Ponnada A Narayana, Flavia Nelson, et al.
Pageof 22

Showing results (201-210 of 216) with videos related to

Sort By:
Pageof 22
The Lancet. Neurology|September 7, 2014
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller, Jerry S Wolinsky, Ludwig Kappos, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosisM S Freedman, J S Wolinsky, P Truffinet, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 23, 2012
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisAaron E Miller, Paul O'Connor, Jerry S Wolinsky, et al.
Multiple Sclerosis and Related Disorders|May 31, 2016
Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studiesMathias Mäurer, Giancarlo Comi, Mark S Freedman, et al.
Neurology|May 25, 2012
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trialM S Freedman, J S Wolinsky, B Wamil, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 1, 1995
Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA134A) in healthy subjects and in patients with chronic airflow limitation. Measurement by 18F-labeling and whole-body gamma-countingV W Pike, F I Aigbirhio, C A Freemantle, et al.
Journal of Neurology|June 29, 2014
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER studyAaron E Miller, Richard Macdonell, Giancarlo Comi, et al.
Multiple Sclerosis and Related Disorders|February 10, 2016
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensionsGiancarlo Comi, Mark S Freedman, Ludwig Kappos, et al.
The Lancet. Neurology|January 28, 2014
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialChristian Confavreux, Paul O'Connor, Giancarlo Comi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 1, 2013
Magnetic resonance imaging outcomes from a phase III trial of teriflunomideJerry S Wolinsky, Ponnada A Narayana, Flavia Nelson, et al.
Pageof 22